Saturday, 7 September 2024

Lunch, 16:45-18:15

• LS-01 | AstraZeneca | Spadolini 3
  Advancing precision medicine in oncology diagnostics: the role of quality HRD testing, ctDNA, and biomarkers in detection and treatment
  001 | Nicola Fusco | Sequencing biomarker testing, guideline updates and AI integration in BC pathology
  002 | Simon Patton | Upholding standards: the critical role of quality and consistency in HRD testing
  003 | Gerhardt Attard | Navigating the maze: challenges and solutions in ctDNA testing

Sunday, 8 September 2024

Breakfast, 07:15-08:15

• BRS-01 | Paige | Spadolini 6
  Revolutionizing pathology through immersive innovation
  001 | Juan Retamero | Revolutionizing pathology through immersive innovation

Lunch, 13:00-14:30

• LS-02 | Daiichi | Spadolini 2
  All you need to HER2 know
  001 | Giuseppe Viale | Welcome and introduction
  002 | Grazia Arpino | Treating cancer in the evolving era of HER2
  003 | Roberto Salgado | Identifying the whole spectrum of HER2: lessons learned
  004 | Josef Rüschoff | Beyond breast: similarities in identifying HER2 in gastric cancer and differences in lung cancer
  005 | Giuseppe Viale | Panel discussion and Q&A
  006 | Giuseppe Viale | Wrap-up and meeting close
• LS-03 | Johnson & Johnson + Diatech Pharmacogenetics | Spadolini 3
  Synergies in sight: navigating challenges of precision medicine via multidisciplinary collaboration in GU oncology
  001 | Gabriella Nesi | Diagnostic challenges and precision medicine in bladder cancer
  002 | Brigida Anna Maiorano | Current molecular landscape of bladder cancer: the oncologist’s perspective
  003 | Gabriella Nesi | Discussion/Q&A
  004 | Glen Kristiansen | Current considerations and challenges in prostate cancer testing
  005 | Rossella Bruno | Molecular testing in GU oncology: pitfalls and analytical strategies
  006 | Gabriella Nesi | Round table and Q&A
• LS-04 | AstraZeneca | Spadolini 4
  Beyond the human eye: diagnostic advances in digital and computational pathology
  001 | Luiza Moore | Welcome & introduction
  002 | Bethany Williams | Seeing eye to (A)I: digital pathology is part of pathology
  003 | Fabio Pagni | Problem-solving digital pathology: attitudes, issues and solutions
  004 | Luiza Moore | Quantitative Continuous Scoring: a new frontier in diagnostics – updates
• LS-05 | MSD | Spadolini 5
  Navigating precision pathology: biomarkers defining treatment, tissue and liquid biopsy synergy, and collaborative patient care
  001 | Matteo Fassan | Welcome & introduction
  002 | Matteo Fassan | Biomarker breakthroughs to treatment transformations: unveiling the shifting landscape in upper GI cancer
  003 | Albrecht Stenzinger | Unlocking the potential of liquid biopsies: overcoming challenges in prostate cancer biomarker testing
  004 | Kaikeen Shiu | Building partnerships in precision medicine: a collaborative approach between medical oncologists and pathologists for patient management
  005 | Matteo Fassan | Panel discussion
  006 | Matteo Fassan | Q&A and closing remarks

• LS-06 | Thermo Fisher Scientific | Spadolini 6
  Precision oncology in every lab: connect next generation pathologists and researchers with NGS biomarker testing
  001 | Nicola Normanno | Welcome & Introduction
  002 | Nicola Normanno | Precision oncology in patient care (including discussion)
  003 | Geetha Monon | Exploring genomic signatures in Malignant Lymphoma: potential advantages for rapid detection of relevant biomarkers
  004 | Wolfram Jochum | Comprehensive genomic profiling (CGP) in high-grade serous carcinoma using peritoneal effusion samples
  005 | Nicola Normanno | Discussion/Q&A

• LS-07 | Vitro.Bio | Spadolini 7
  Addressing routine challenges in modern pathology
  001 | Guido Sauter | Introduction
  002 | Karen Villar Zarra | Tackling routine challenges: the power of automated staining
  003 | Miguel Angel Idoate Gastearena | Advanced HPV detection: molecular pathology strategies for effective screening
  004 | Melchor Saiz-Pardo | Pathology in the digital age: overcoming security challenges with cutting-edge solutions
  005 | Guido Sauter | Discussion

Evening, 19:30-20:30

• ES-01 | Epredia | Spadolini 5
  Digital transformation: journey to a digital workflow
  001 | Catarina Eloy | Digitizing workflow: steps taken in the pre-analytical and analytical stages for workflow optimization, ensuring a successful digital pathology project

Monday, 9 September 2024

Breakfast, 07:15-08:15

• BRS-02 | Eli Lilly | Spadolini 6
  Power hour: the importance of pathologists for the success of clinical studies
  001 | Lorenzo Gerratana | Welcome and introduction
  002 | Lorenzo Gerratana | Introduction into clinical study management
  003 | Giancarlo Pruneri | Biomarker testing in clinical trials
  004 | Albrecht Stenzinger | IVDR requirements for clinical studies
  005 |  Lorenzo Gerratana | Q&A and Round-table discussion
  006 | Albrecht Stenzinger | Summary and close
• BRS-03 | Roche | Spadolini 7
  Improving the diagnosis of B Cell lymphomas in routine pathology practice: advances in clonality evaluation
  001 | Teresa Marafioti & Marta Cañamero | Improving the diagnosis of B Cell lymphomas in routine pathology practice: advances in clonality evaluation

Lunch, 13:00-14:30

• LS-08 | Roche Diagnostics + Johnson & Johnson | Spadolini 2
  Pathways to precision: practical strategies for optimizing diagnostic excellence
  001 | Angelo Paolo Dei Tos | Introduction: testing pathway and patient leakage points
  002 | Deniz Nart | Precision oncology in lung cancer: enhancing patient outcomes through NGS and biomarker driven therapies - Ege University experience
  003 | Sylvie Lantuejoul | Optimizing the workflow to reduce failure rates
  004 | Isabelle Vanden Bempt | RNA-Based sequencing for simultaneous detection of clinically actionable fusions and mutations in solid tumours
  005 | Angelo Paolo Dei Tos | Round table and Q&A
• LS-09 | AstraZeneca | Spadolini 3
  Exploring the expanding applications of ctDNA and pathway mutations in breast cancer diagnostics
  001 | Espen Walker | Welcome and introduction
  002 | Elena Guerini Rocco | The utility of ctDNA in breast cancer
  003 | Nicola Fusco | Emerging testing strategies for the optimization of patient profiling in HR+/HER2- breast cancer
  004 | Espen Walker | Closing remarks
• LS-10 | 3DHistech | Spadolini 4
  Digital Pathology, IHC and Cytology
  001 | Catarina Eloy | Postponing evolution: why are we choosing to ignore the need for a digital transformation in pathology?
  002 | Felix Offner | Experiences with the implementation of digital cytology with Datexim and 3DHistech in Feldkirch, Austria
  003 | Yukako Yagi | Digital IHC, digital microCT
• LS-11 | gsk | Spadolini 5
  Guiding clinical outcomes in gynaecological cancers with early and accurate biomarker testing, including case-based examples
  001 | Gian Franco Zannoni | Introduction to biomarker testing in gynaecological cancers
  002 | Josef Rüschoff | Biomarker testing in endometrial cancer: current status and key considerations
  003 | Vanda Salutari | Treatment options according to molecular classification in endometrial cancer: clinical perspective and case study
  004 | Gian Franco Zannoni | Panel discussion on biomarker testing in endometrial cancer
  005 | Isabelle Treilleux | Biomarker testing in ovarian cancer: focus on HRD and BRCA
  006 | Vanda Salutari | Impact of biomarker testing on patient outcomes in ovarian cancer: clinical perspective and case study
  007 | Gian Franco Zannoni | Panel discussion on biomarker testing in ovarian cancer
• LS-12 | Agilent Technologies | Spadolini 7
  Changing testing in gastric cancer: a practical review
  001 | Mar Iglesias | Welcome & focus
  002 | Manuel Rodriguez-Justo | Case 1: The critical role of preanalytics in the context of case referrals
  003 | Matteo Fassan | Case 2: Assessing case heterogeneity effectively: from number of biopsies to tumour staging
  004 | Mar Iglesias | Q&A and closing remarks

Tuesday, 10 September 2024

Lunch, 13:00-14:30

• LS-13 | Roche | Spadolini 2
  Precision diagnostics in ovarian cancer: traversing from testing to treatment
  001 | Michelle Shiller & Domenica Lorusso
• LS-14 | AstraZeneca | Spadolini 3
  NSCLC: the evolution and expansion of testing across the care continuum
  001 | Alexander Yarunin | Welcome and introduction
  002 | Giuseppe Perrone | Navigating the evolving NSCLC testing landscape: guidance for the detection of driver and acquired resistance mutations
  003 | Nicola Normanno | Plasma ctDNA testing in lung cancer: application across the care continuum
  004 | Elena Guerini Rocco | Evaluating pathological complete response
  005 | Alexander Yarunin | Closing remarks
• LS-15 | Astellas | Spadolini 4
  The Pathologist's loom: weaving CLDN18.2 into practice
  001 | Matteo Fassan | Welcome and introductions
  002 | Lorenzo Fornaro | Unravelling the gastric cancer and GEJ tapestry: clinical insights into the current treatment landscape and emerging biomarkers
  003 | Philippe Taniere | Stitching the narrative: CLDN18.2 in the fabric of G/GEJ adenocarcinoma
  004 | Matteo Fassan | The Pathologist’s canvas: exploring CLDN18.2 expression patterns in G/GEJ adenocarcinoma
  005 | Matteo Fassan | Q&A session
  006 | Matteo Fassan | Summary and close

• LS-16 | Illumina | Spadolini 5
  Illumina's journey in precision pathology: from targeted panels to whole genome sequencing
  001 | Giancarlo Pruneri | Empowering precision pathology: genomic tools
  002 | Giulia Cangi | Enhancing precision: leveraging small panels for oncology testing
  003 | Sergio Villatoro | Maximizing insights: comprehensive genomic profiling
  004 | Greg Elgar | Charting the future of precision pathology: whole genome sequencing strategies
  005 | Giancarlo Pruneri | Unveiling the potential: panel discussion on the future of precision pathology
• LS-17 | Amgen | Spadolini 6
  The future of pathology: liquid biopsy, novel biomarkers, and tumour-agnostic therapies
  001 | Frédérique Penault-Llorca | Welcome and introduction
  002 | Lukas Bubendorf | Liquid biopsy in NSCLC: a discourse on controversies and advancements
  003 | Irene Esposito | The next frontier: FGFR2b and CLDN18.2 as promising biomarkers for G/GEJ cancers
  004 | Albrecht Stenzinger | Unlocking the power of MTAP-homozygous deletion: a tumour-agnostic biomarker
  005 | Frédérique Penault-Llorca | Panel discussion and Q&A
  006 | Frédérique Penault-Llorca | Summary and close
• LS-18 | Agilent Technologies | Spadolini 7
  How can scalable, open digital pathology solutions advance diagnostic quality and efficiency in pathology practice?
  001 | Jake Eden | Welcome & Agilent digital pathology focus
  002 | Robert D. Goldin | Digitising liver pathology: from research to clinical delivery
  003 | Teemu Tolonen | Multi-site, multi-AI pathology: quality, efficiency, and lead-time impact through scaled algorithm deployment
  004 | Bert Van Der Vegt | Integration of computational pathology algorithms in the clinical digital pathology workflow: connecting the dots
  005 | Holger Moch | Evolving role of digital pathology in anatomic and molecular pathology laboratories
  006 | Douglas Clark| Panel discussion

• Siemens Healthineers AG | 9 September 2024, 09:30-09:50, HotSpot stage at exhibition area
  Navigating the galaxy of data: a journey through digital pathology
  Dr. Svenja Lippok, Germany

• SOPHiA GENETICS | 9 September 2024, 10:00-10:20, HotSpot stage at exhibition area
  Building evidence and confidence in liquid biopsy solutions
  Dr. Alexander Yarunin, United Kingdom
  Verena Schramm, Germany
• SOPHiA GENETICS | 10 September 2024, 09:30-09:50, HotSpot stage at exhibition area
  Insights with impact: empowering laboratories with robust CGP solutions
  Verena Schramm, Germany
• Sysmex Europe SE | 10 September 2024, 10:00-10:20, HotSpot stage at exhibition area
  Liquid biopsy in breast cancer patient care
  Maria De Bonis, Italy
  Prof. Angelo Minucci, Italy

Roche (booth no. 15) will offer 6 Meet-the-Expert talks during the follwing times:

• Sunday, Sep 8, 13:10 - 13:30
  PIK3CA; Leveraging emerging insights to drive personalised care
  Dr. Nicola Fusco, Italy
• Sunday, Sep 8, 14:00-14:20
  The Roche Digital LightCycler: a real world performance evaluation in a Dutch hospital laboratory
  Dr. Wouter Pattje, USA
• Monday, Sep 9, 14:00-14:20
  Advancing precision medicine: PathAI and Roche Collaborate for AI-powered companion diagnostics
  Eric Walk, USA
  Michael Rivers, USA
• Monday, Sep 9, 13:10- 13:30
  Seamless integration of Ibex's AI algorithms within Roche's navify® Digital Pathology
  Michael Rivers, USA
  Stuart Shand, The Netherlands
• Monday, Sep 9, 16:40 - 17:00
  Unlock the power of in-house comprehensive genomic profiling with AVENIO Tumor Tissue CGP Kit V2 and the new foundation medicine HRD signature
  Robert Bulte, Switzerland
  Muriel De Vos, Switzerland
• Tuesday, Sep 10, 13:10 - 13:30
  Gastric cancer testing landscape in 2024 and beyond
  Mar Iglesias, Spain